Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring.
The clinical characteristics and prognosis remain unclear for nasal-type NK/T-cell lymphoma of Waldeyer ring (WR-NKTL). The aim of this study is to determine the clinical features and outcome. Ninety-one patients with WR-NKTL were reviewed. According to the Ann Arbor system, 15, 56, 12, and 8 patients had stage I, II, III, and IV. Of patients with stage I and II, 54 received combined chemotherapy and radiotherapy (CMT), 13 received radiotherapy alone, and 4 patients received chemotherapy alone. All 20 patients with stage III/IV received primary chemotherapy. The disease is characterized by predominance in young males, good performance, a propensity for nodal involvement, frequent stage II through IV diseases, low frequency of elevated LDH, low-risk international prognostic index (IPI), high sensitivity to radiotherapy, and intermediate sensitivity to chemotherapy. The 5-year overall survival and progression-free survival for all patients were 65% and 51%, respectively. The age, B symptoms, stage, and IPI were important prognostic factors. CMT tended to improve the survival compared with radiotherapy alone for patients with stage I and II diseases. Both nodal involvement and distant extranodal dissemination were the primary failure patterns. WR-NKTL appears to have distinct clinical characteristics and favorable outcomes.
Li
Ye-Xiong
YX
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, People's Republic of China. yexiong@yahoo.com
Fang
Hui
H
Liu
Qing-Feng
QF
Lu
Jiade
J
Qi
Shu-Nan
SN
Wang
Hua
H
Jin
Jing
J
Wang
Wei-Hu
WH
Liu
Yue-Ping
YP
Song
Yong-Wen
YW
Wang
Shu-Lian
SL
Liu
Xin-Fan
XF
Feng
Xiao-Li
XL
Yu
Zi-Hao
ZH
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology*; D016399:Lymphoma, T-Cell / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009669:Nose Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000532:radiotherapy*; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents